Presented at the AACR Conference in April 2021, this poster summarizes the Alloplex SUPLEXA Therapeutic Cell Platform and documents the increased diversity of the TCR clonotypes present in the ab and gd T cell populations, relative to the starting PBMC, thus demonstrating the hallmarks of an antigen driven T cell expansion during manufacturing.
Conclusions:
SUPLEXA cells represent an easy to manufacture autologous anti-tumor cell therapy that overcomes many of the limitations associated with previous autologous therapies. They possess a broad anti-tumor activity at exceedingly low E:T ratios with specific production of IFN-γ, IL-6 and IL-8 during tumor cell killing. Ongoing efforts are underway to understand the relative contributions of NK cells, NK-T-like, γδ T cells and CD8+ T cells to broad tumor cytolysis and the antigen-specificities seen with SUPLEXA cells from multiple donors. Planning for a first in human clinical trial is currently underway.